BAX Stock Forecast: Baxter International, Inc. Price Predictions for 2026-2027
The 15 Wall Street analysts covering Baxter International, Inc. hold a median 12-month price target of $26 — +2.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 94 of 100 as at 21 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Baxter International, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.
Quality (50): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
BAX stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on BAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +2.4% from it.
Of the 20 most recent actions, 11 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Nov 2026 | Barclays | Maintains | Underweight | $20 → $23 |
| 30 Oct 2026 | JP Morgan | Maintains | Neutral | $26 → $25 |
| 30 Oct 2026 | Wells Fargo | Maintains | Equal-Weight | $23 → $25 |
| 7 Oct 2026 | Barclays | Initiates | Underweight | — |
| 5 Oct 2026 | Citigroup | Maintains | Neutral | $28 → $27 |
| 31 July 2026 | Citigroup | Upgrade | Neutral | $17 → $28 |
| 31 July 2026 | Stifel | Maintains | Hold | $24 → $28 |
| 31 July 2026 | TD Cowen | Maintains | Hold | $24 → $29 |
| 31 July 2026 | Wells Fargo | Maintains | Equal-Weight | $19 → $23 |
| 28 July 2026 | Stifel | Maintains | Hold | $19 → $24 |
| 28 July 2026 | UBS | Maintains | Neutral | $19 → $25 |
| 27 July 2026 | TD Cowen | Maintains | Hold | $20 → $24 |
| 15 July 2026 | Goldman Sachs | Maintains | Neutral | $19 → $21 |
| 6 July 2026 | Evercore ISI Group | Maintains | Outperform | $22 → $24 |
| 28 May 2026 | Citigroup | Downgrade | Sell | — |
| 4 May 2026 | Barclays | Maintains | Overweight | — |
| 6 Apr 2026 | Evercore ISI Group | Maintains | Outperform | — |
| 11 Mar 2026 | Citigroup | Maintains | Neutral | — |
| 17 Feb 2026 | Goldman Sachs | Maintains | Neutral | — |
| 13 Feb 2026 | Barclays | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for BAX.
This page is one stock. Monday covers all of them.
BAX appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
BAX vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Baxter International, Inc. returned +46.0% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
BAX analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.2×
- Price / book
- 2.1×
- EV / EBITDA
- 10.9×
Cheaper than 62% of US stocks
Cheaper than 42% of US stocks
Cheaper than 52% of US stocks
- Revenue growth (YoY)
- 5.0%
- Earnings growth (YoY)
- —
- Gross margin
- 34.9%
- Operating margin
- 7.6%
- Net margin
- −6.2%
Higher than 41% of US stocks
Higher than 42% of US stocks
Higher than 59% of US stocks
Higher than 23% of US stocks
- Return on equity
- −9.0%
- Return on assets
- 2.7%
- Dividend yield
- 0.2%
Higher than 37% of US stocks
Higher than 62% of US stocks
Higher than 2% of US dividend payers
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Baxter International, Inc. has a market value of $13.1B and an enterprise value of $19.9B.
Revenue in the twelve months to 30 June 2026: $11.5B. The latest quarter grew 5.3% year on year.
Net income over the same four quarters: −$1.1B, a −9.3% net margin.
Diluted earnings per share, trailing twelve months: −$2.07.
Free cash flow in the twelve months to 30 June 2026: $812.0M, after $504.0M of capital spending.
Baxter International, Inc. spent $184.0M on dividends in the twelve months to 30 June 2026.
forward P/E: 12.7× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.15%.
Baxter International, Inc. employs 37,500 people — $306K of revenue per employee.
Data provided by Twelve Data
BAX and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at BAX’s peer groups, ranked by the model: healthcare stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Baxter International, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about BAX
What is the BAX stock price forecast for 2026-2027?
The 15 Wall Street analysts covering Baxter International, Inc. have a median 12-month price target of $26, with estimates ranging from $23 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is BAX stock a buy right now?
Of the 15 analysts covering Baxter International, Inc., 2 rate it a Buy, 12 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Baxter International, Inc. 94 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank BAX?
As at 21 Nov 2026, Baxter International, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).
Will BAX stock go up?
No one can know that. What the data says: the median 12-month target from 15 analysts implies +2.4% from the last close, and Ticker Nerd's factor model ranks Baxter International, Inc. 94 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the BAX stock forecast for 2030?
No analyst covering Baxter International, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $23 to $40 over the next 12 months.
How has BAX stock performed over the past year?
Baxter International, Inc. returned +46.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Baxter International, Inc. do?
Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices.
About Baxter International, Inc.
Baxter International Inc. is a global healthcare company focused on providing essential medical products and technologies used in hospitals, clinics, surgery centers, pharmacies, and home-care settings. Baxter International Inc. develops and supplies infusion systems, sterile intravenous solutions, injectable pharmaceuticals, parenteral nutrition therapies, advanced surgery products, patient monitoring and diagnostic technologies, smart beds, and respiratory care devices. The company also supports renal and acute care through therapies and connected solutions that help clinicians deliver treatment across a wide range of care environments. Its portfolio is designed to support everyday healthcare delivery, from critical care and procedural settings to long-term and ambulatory care. Baxter International Inc. plays an important role in the medical technology market by supplying products that are widely used in routine treatment, life-sustaining therapy, and hospital infrastructure.
CEO Mr. Andrew P. Hider · 37,500 employees · United States · https://www.baxter.com